Inhibition of matrix metalloproteinases and inducible nitric oxide synthase by andrographolide in human osteoarthritic chondrocytes

Modern Rheumatology

Volumn 23, Issue 6, 2013, Pages 1124-1132

  Ding, Qian Hai ^a   Ji, Xiao Wei ^a   Cheng, Ye ^a   Yu, Yuan Guan ^a   Qi, Yi Ying ^a   Wang, Xiang Hua ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Andrographolide; Inducible nitric oxide synthase; Matrix metalloproteinase; Nuclear factor kappa B; Osteoarthritis

Indexed keywords

CARTILAGE, ARTICULAR; CHONDROCYTES; DITERPENES; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; NITRIC OXIDE SYNTHASE TYPE II; OSTEOARTHRITIS, KNEE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84894384546     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0807-6     Document Type: Article

References (39)

1. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007;213: 626-34.
2. Lee R, Kean WF. Obesity and knee osteoarthritis. Inflammopharmacology. 2012.
3. Loeser RF. Aging and osteoarthritis. Curr Opin Rheumatol. 2011;23: 492-6.
4. Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthr Res Ther 2009;11.
5. Chevalier X, Conrozier T, Richette P. Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy. Arthr Res Ther. 2011;13:124.
6. Dahlberg L, Billinghurst RC, Manner P, Nelson F, Webb G, Ionescu M, et al. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthr Rheum. 2000;43: 673-82.
7. Smith GN Jr. The role of collagenolytic matrix metalloproteinases in the loss of articular cartilage in osteoarthritis. Front Biosci. 2006;11: 3081-95.
8. Poole AR. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am. 2003;29: 803-18.
9. Abramson SB. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthr Res Ther. 2008;10(Suppl 2):S2.
10. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest. 1997;100: 2417-23.
11. Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol. 1998;10: 263-8.
12. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269: 4705-8.
13. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB. NF-kappaB signaling: multiple angles to target OA. Curr Drug Targets. 2010;11: 599-613.
14. Dai GF, Zhao J, Jiang ZW, Zhu LP, Xu HW, Ma WY, et al. Antiinflammatory effect of novel andrographolide derivatives through inhibition of NO and PGE(2) production. Int Immunopharmacol 2011; 11(12): 2144-2149.
15. Jiang X, Yu P, Jiang J, Zhang Z, Wang Z, Yang Z, et al. Synthesis and evaluation of antibacterial activities of andrographolide analogues. Eur J Med Chem. 2009;44: 2936-43.
16. Lee YC, Lin HH, Hsu CH, Wang CJ, Chiang TA, Chen JH. Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3 K/Akt signaling pathway. Eur J Pharmacol. 2010;632: 23-32.
17. Shi MD, Lin HH, Chiang TA, Tsai LY, Tsai SM, Lee YC, et al. Andrographolide could inhibit human colorectal carcinoma Lovo cells migration and invasion via down-regulation of MMP-7 expression. Chem Biol Interact. 2009;180: 344-52.
18. Burgos RA, Hancke JL, Bertoglio JC, Aguirre V, Arriagada S, Calvo M, et al. Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. Clin Rheumatol. 2009;28: 931-46.
19. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthr Rheum. 1986;29: 1039-49.
20. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthr Rheum. 1991;34: 505-14.
21. Lieberthal W, Triaca V, Koh JS, Pagano PJ, Levine JS. Role of superoxide in apoptosis induced by growth factor withdrawal. Am J Physiol. 1998;275:F691-702.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25: 402-8.
23. Palmieri B, Lodi D, Capone S. Osteoarthritis and degenerative joint disease: local treatment options update. Acta Biomed. 2010;81: 94-100.
24. Malemud CJ. Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging. 2010;27: 95-115.
25. Aigner T, Sachse A, Gebhard PM, Roach HI. Osteoarthritis: pathobiology-targets and ways for therapeutic intervention. Adv Drug Deliv Rev. 2006;58: 128-49.
26. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274: 21491-4.
27. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002;3: 207-14.
28. Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, et al. Matrix metalloproteinases in arthritic disease. Arthr Res. 2002;4(Suppl 3):S39-49.
29. Takaishi H, Kimura T, Dalal S, Okada Y, D'Armiento J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol. 2008;9: 47-54.
30. Pratheeshkumar P, Kuttan G. Andrographolide inhibits human umbilical vein endothelial cell invasion and migration by regulating MMP-2 and MMP-9 during angiogenesis. J Environ Pathol Toxicol Oncol. 2011;30: 33-41.
31. Lee KC, Chang HH, Chung YH, Lee TY. Andrographolide acts as an anti-inflammatory agent in LPS-stimulated RAW264.7 macrophages by inhibiting STAT3-mediated suppression of the NF-kappaB pathway. J Ethnopharmacol. 2011;135: 678-84.
32. Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthr Cartil. 2003;11: 747-55.
33. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthr Rheum. 1998;41: 1275-86.
34. Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthr Res Ther. 2003;5: 94-103.
35. Malfait AM, Liu RQ, Ijiri K, Komiya S, Tortorella MD. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem. 2002;277: 22201-8.
36. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthr Res. 2002;4: 157-64.
37. Tian B, Brasier AR. Identification of a nuclear factor kappa B-dependent gene network. Recent Prog Horm Res. 2003;58: 95-130.
38. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18: 2195-224.
39. Lee WR, Chung CL, Hsiao CJ, Chou YC, Hsueh PJ, Yang PC, et al. Suppression of matrix metalloproteinase-9 expression by andrographolide in human monocytic THP-1 cells via inhibition of NF-kappaB activation. Phytomedicine 2012.